Minerva Neurosciences (NERV) Accumulated Expenses (2013 - 2026)
Minerva Neurosciences posted quarterly Accumulated Expenses of $40750.0 for Q1 2026, down 33.41% year-on-year from $61199.0 in Q1 2025, and down 96.1% on a QoQ basis from $1.0 million in Q3 2025.
Minerva Neurosciences (NERV) has 14 years of Accumulated Expenses data on file, last reported at $40750.0 in Q1 2026.
- For the quarter ending Q1 2026, Accumulated Expenses fell 33.41% year-over-year to $40750.0; the trailing twelve-month figure through Mar 2026 stood at $40750.0 (down 33.41% YoY), and the FY2024 full-year result was $363181.0, down 38.52% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $40750.0, down from $1.0 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $1.1 million in Q3 2022 and bottomed at $14832.0 in Q4 2022.
- The 5-year median for Accumulated Expenses is $223491.5 (2023), against an average of $401186.6.
- Peak annual rise in Accumulated Expenses reached 3883.07% in 2023, while the deepest fall reached 92.98% in 2023.
- A 5-year view of Accumulated Expenses shows it stood at $14832.0 in 2022, then jumped by 3883.07% to $590769.0 in 2023, then tumbled by 38.52% to $363181.0 in 2024, then soared by 187.53% to $1.0 million in 2025, then slumped by 96.1% to $40750.0 in 2026.
- The last three Accumulated Expenses figures came in at $40750.0 (Q1 2026), $1.0 million (Q3 2025), and $756394.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40,750.00 |
| Sep 30, 2025 | 1.04 Mn |
| Jun 30, 2025 | 756,394.00 |
| Mar 31, 2025 | 61,199.00 |
| Dec 31, 2024 | 363,181.00 |
| Sep 30, 2024 | 966,723.00 |
| Jun 30, 2024 | 727,302.00 |
| Mar 31, 2024 | 36,126.00 |
| Dec 31, 2023 | 590,769.00 |
| Sep 30, 2023 | 80,241.00 |
| Jun 30, 2023 | 83,802.00 |
| Mar 31, 2023 | 396,494.00 |
| Dec 31, 2022 | 14,832.00 |
| Sep 30, 2022 | 1.14 Mn |
| Jun 30, 2022 | 65,721.00 |
| Mar 31, 2022 | 47,984.00 |
| Sep 30, 2021 | 76,478.00 |
| Jun 30, 2021 | 766,522.00 |
| Mar 31, 2021 | 61,268.00 |
| Sep 30, 2020 | 111,448.00 |
| Jun 30, 2020 | 832,148.00 |
| Mar 31, 2020 | 60,247.00 |
| Sep 30, 2019 | 83,367.00 |
| Jun 30, 2019 | 83,164.00 |
| Mar 31, 2019 | 251,630.00 |
| Sep 30, 2018 | 75,714.00 |
| Jun 30, 2018 | 68,438.00 |
| Mar 31, 2018 | 12,930.00 |
| Dec 31, 2017 | 20,508.00 |
| Sep 30, 2017 | 37,827.00 |
| Jun 30, 2017 | 66,318.00 |
| Mar 31, 2017 | 40,860.00 |
| Dec 31, 2016 | 49,523.00 |
| Sep 30, 2016 | 56,463.00 |
| Jun 30, 2016 | 58,750.00 |
| Mar 31, 2016 | 190,571.00 |
| Dec 31, 2015 | 58,750.00 |
| Sep 30, 2015 | 106,250.00 |
| Jun 30, 2015 | 212,500.00 |
| Mar 31, 2015 | 546,761.00 |
| Dec 31, 2014 | 327,960.00 |
| Sep 30, 2014 | 17,818.00 |
| Jun 30, 2014 | 2.34 Mn |
| Dec 31, 2013 | 24,276.00 |